SENSEI BIOTHERAPEUTICS INC. - COMMON STOCK

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

01 يونيو 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference

25 مايو 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

10 مايو 2022 06:30:01 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights

10 مارس 2022 06:30:01 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors

09 مارس 2022 15:05:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

03 مارس 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit

11 فبراير 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Executive Promotions

06 يناير 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award

16 ديسمبر 2021 08:01:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index

13 ديسمبر 2021 15:01:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

19 نوفمبر 2021 15:02:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

12 نوفمبر 2021 06:02:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights

09 نوفمبر 2021 07:54:48 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021

03 نوفمبر 2021 08:01:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

01 أكتوبر 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program

04 أغسطس 2021 06:45:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors

02 أغسطس 2021 07:01:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs

28 يونيو 2021 15:05:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

19 مايو 2021 16:03:00 بحسب Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update

12 مايو 2021 06:41:00 بحسب Nasdaq GlobeNewswire